Lung cancer screening

Median Technologies to Participate and Speak at the 2024 European Congress of Radiology (ECR), February 28 – March 3, Vienna, Austria

Retrieved on: 
Monday, February 26, 2024
Software, Radiology, Hardware, Data Management, Oncology, Biometrics, Technology, Medical Devices, Artificial Intelligence, Health Technology, Biotechnology, Other Technology, Health, Cloud, Lung cancer, Sorbonne University, Intelligence cycle, LCS, AP-HP, AI, Lung cancer screening, Lab, Hospital, Exhibition, ECR, Foch Hospital, Knowledge, Congress, Diagnosis, Deep learning, ESR, HCC, Artificial intelligence, Research, PACS

Median Technologies (FR0011049824, ALMDT, PEA/SME eligible) announces today that the Company will be participating and speaking at the premier European radiology conference, the European Congress of Radiology (ECR), being held in Vienna, Austria, February 28 – March 3, 2024.

Key Points: 
  • Median Technologies (FR0011049824, ALMDT, PEA/SME eligible) announces today that the Company will be participating and speaking at the premier European radiology conference, the European Congress of Radiology (ECR), being held in Vienna, Austria, February 28 – March 3, 2024.
  • Philippe Grenier, Thoracic Radiologist and Head of the Artificial Intelligence project, Foch Hospital, Saint Cloud, France and Pr.
  • The European Congress of Radiology (ECR) organized by the European Society of Radiology (ESR) is the premier European event in radiology and the second largest in the world.
  • The congress conveys more than 20,000 with a split of more than 10,000 professional delegates (radiologists, technologists etc.

Median Technologies Reports 2023 Revenue and Summarizes 2024 Strategic Outlook

Retrieved on: 
Monday, January 29, 2024
Biometrics, Radiology, Biotechnology, Oncology, Health, Medical Devices, Health Technology, Clinical Trials, Mortality, ChromeOS, Bank statement, Lung cancer screening, HCC, Patient, Machine learning, Imaging, Artificial intelligence, REALITY, Partnership, Cave rescue, COVID-19, MRMC, Stand-alone, ESMO, AI, Lung cancer, Big Pharma, Growth, LCS, Hepatocellular carcinoma, Medical device, AUC, Acceleration, EIB, Small Business Saturday, Hospital, FDA, BofA Securities, Diagnosis, CE, European Investment Bank, Fine chemical

Median Technologies (FR0011049824, ALMDT, PEA/SME eligible) announces its 2023 revenue, outlining both its strategic outlook and key milestones for 2024.

Key Points: 
  • Median Technologies (FR0011049824, ALMDT, PEA/SME eligible) announces its 2023 revenue, outlining both its strategic outlook and key milestones for 2024.
  • Fredrik Brag, Chief Executive Officer and Founder of Median Technologies, commented: "In Q4 2023, our iCRO1 business achieved record-high order intake, which increased significantly our backlog.
  • We expect to return to growth in 2024 on the back of a decline in 2023 revenue due to soft order intake in China caused by the Covid lockdowns in 2022 and H1 2023."
  • The Standalone study will be finalized in Q2 2024 and the MRMC study in Q3 2024.

Median Technologies to Speak at the IASLC 2023 North America Conference on Lung Cancer (NACLC), Dec. 1-3, Chicago, IL, USA, with two Presentations

Retrieved on: 
Thursday, November 30, 2023
Technology, Medical Devices, Other Technology, Software, Other Health, Radiology, Health, Artificial Intelligence, Oncology, NACLC, Magnificent Mile, International Association, Bent Image Lab, Conference, Lung cancer screening, Lung cancer

Median Technologies (Paris:ALMDT) announced today that the Company will be presenting two scientific posters at the 2023 North America Conference on Lung Cancer (NACLC) being held in Chicago (Chicago Marriott Downtown Magnificent Mile), Il, USA, Dec. 1 – 3.

Key Points: 
  • Median Technologies (Paris:ALMDT) announced today that the Company will be presenting two scientific posters at the 2023 North America Conference on Lung Cancer (NACLC) being held in Chicago (Chicago Marriott Downtown Magnificent Mile), Il, USA, Dec. 1 – 3.
  • The NACLC is organized by the International Association for the Study of Lung Cancer (IASLC), a global multidisciplinary association dedicated to eradication of all forms of lung cancers.
  • The Company will give two poster presentations on December 2nd from 5:40 to 6:55 pm CT.
    Poster PP01.49: End to End AI model for Nodule Detection and Characterization in Lung Cancer Screening: Performances and Subpopulation Analysis
    Median’s eyonis™ and Imaging Lab teams will attend the event and be available for presenting the latest advances of eyonis® AI/ML tech based SaMD and the Imaging Lab developments.

Northwell Opens $52M Cancer Center, Multispecialty Practice in Queens

Retrieved on: 
Tuesday, November 28, 2023
General Health, Hospitals, Health, Practice Management, Oncology, Queens Boulevard, Hindi, Oncology nursing, North Shore University Hospital, Gynaecology, Cancer Institute, LIJ, New Yorker, Head, Cardiology, Endocrinology, Genetic counseling, Surgical oncology, Hematology, Elective surgery, DEXA, Internal medicine, Urology, Breast cancer, Google Images, Patient, Multimedia, Gastrointestinal cancer, Colorectal surgery, Kimelman Cancer Institute, Neurology, Heart, Obstetrics, Rheumatology, MD Anderson Cancer Center, Rehabilitation, Bariatrics, Lung cancer screening, Gastroenterology, HIV, Neurosurgery, Cancer, QMA, MRI, Social work, Hospital, PET, General surgery, STARS, Estate (law), Nursing, Management, MD, Northwell Health

As part of the new cancer center, Queens Medical Associates (QMA), a member of the Northwell Health Cancer Institute, will move its highly regarded hematology and oncology practice, located in Fresh Meadows for over 30 years, to Rego Park.

Key Points: 
  • As part of the new cancer center, Queens Medical Associates (QMA), a member of the Northwell Health Cancer Institute, will move its highly regarded hematology and oncology practice, located in Fresh Meadows for over 30 years, to Rego Park.
  • Northwell treats about 19,000 New Yorkers with cancer each year, more than any other cancer provider in the state.
  • “We’re excited to open a new outpatient cancer center in the heart of Queens to deliver the best cancer care close to where people live,” said Richard Barakat, MD , physician-in-chief and executive director of the Northwell Health Cancer Institute.
  • “Northwell is uniquely positioned to care for patients in Queens – one of the most diverse places in the country.

AI Identifies Non-smokers at High Risk for Lung Cancer

Retrieved on: 
Wednesday, November 22, 2023
Deep learning, Medicine, Lung, Health, RSNA, Smoker, Research, MGH, National academy, Incidence, American Cancer Society, National Comprehensive Cancer Network, Risk, Disease, Hospital, Mortality, Serum, B.A, Patient, Respiratory tract infection, Tobacco, Smoke, Artificial intelligence, Knowledge Organization (journal), Non-Smokers' Rights Association, USPSTF, Prostate, Lung cancer screening, Lung cancer, Newsroom, Harvard Medical School, Diagnosis, CIRC, Massachusetts General Hospital, Medicare, Chronic obstructive pulmonary disease, Biomarker, Cancer, Society, Radiology, Radiation, Education, Risk management, Medical imaging, Boston

The American Cancer Society estimates about 238,340 new cases of lung cancer in the United States this year and 127,070 lung cancer deaths.

Key Points: 
  • The American Cancer Society estimates about 238,340 new cases of lung cancer in the United States this year and 127,070 lung cancer deaths.
  • Existing lung cancer risk scores require information that is not readily available for most individuals, such as family history of lung cancer, pulmonary function testing or serum biomarkers.
  • For the study, CIRC researchers set out to improve lung cancer risk prediction in never-smokers by testing whether a deep learning model could identify never-smokers at high risk for lung cancer, based on their chest X-rays from the electronic medical record.
  • The high-risk group well exceeded the 1.3% six-year risk threshold where lung cancer screening CT is recommended by National Comprehensive Cancer Network guidelines.

EarlySign Announces Launch of LungFlag™

Retrieved on: 
Wednesday, November 8, 2023
Geisinger, Informatics, Lung cancer, TEL, Colorectal cancer, Diabetes, Health, Lung cancer screening, Patient satisfaction, Public, EHR, Cancer, Patient, Diagnosis, Pharmaceutical industry, Nursing, Medical imaging

TEL AVIV, Israel and DANVILLE, Pa., Nov. 8, 2023 /PRNewswire/ -- Medial EarlySign, a pioneering company developing AI-based clinical predictive analytics, and Geisinger, an integrated health care system, announced today the launch of the LungFlag AlgoMarker. LungFlag identifies patients at high risk for respiratory or pulmonary illnesses, such as lung cancer, by analyzing routine data from the electronic health record (EHR). 

Key Points: 
  • TEL AVIV, Israel and DANVILLE, Pa., Nov. 8, 2023 /PRNewswire/ -- Medial EarlySign , a pioneering company developing AI-based clinical predictive analytics, and Geisinger , an integrated health care system, announced today the launch of the LungFlag AlgoMarker.
  • Working together with Geisinger, Medial EarlySign designed the LungFlag program to enable earlier interventions.
  • Early intervention is central to Geisinger's value-based care model, leading to improved clinical outcomes, higher patient satisfaction and decreased costs.
  • LungFlag is the latest addition to EarlySign's expanding platform of validated clinical solutions impacting the early diagnosis of serious diseases.

Dr. Maximilian Diehn Receives LUNGevity's 2023 Lung Cancer Early Detection Award

Retrieved on: 
Wednesday, November 1, 2023
Gold, MPH, Lung cancer, Doctor of Philosophy, Lung cancer screening, Research, Quality of life, Methylation, Disease, Partnership, Biopsy, CT, Blood, Cancer, Patient, Diagnosis, Prognosis, DNA, Uranium mining, Medical imaging, MD

WASHINGTON, Nov. 1, 2023 /PRNewswire/ -- LUNGevity Foundation, the nation's leading lung cancer-focused nonprofit organization, is proud to announce Maximilian Diehn, MD, PhD, as the recipient of LUNGevity's 2023 Lung Cancer Early Detection Award. Dr. Diehn's work builds on LUNGevity's 15-year focus on funding research into the early detection of lung cancer and continues its investment in developing a noninvasive blood test to detect lung cancer in its earliest stages. 

Key Points: 
  • WASHINGTON, Nov. 1, 2023 /PRNewswire/ -- LUNGevity Foundation, the nation's leading lung cancer-focused nonprofit organization, is proud to announce Maximilian Diehn, MD, PhD, as the recipient of LUNGevity's 2023 Lung Cancer Early Detection Award.
  • The 2023 Lung Cancer Early Detection Award recipient is:
    Dr. Diehn and his team have already developed three different blood tests for the early detection of lung cancer.
  • "This award program supports research to help us reimagine the early detection of lung cancer and make it easier for doctors to find lung cancer in earlier stages," said Dr. Basu Roy.
  • LUNGevity's 2023 Lung Cancer Early Detection Award is funded in partnership with Carla and Alan Braverman.

IMIDEX Announces FDA 510(k) Clearance for VisiRad™ XR, an AI-powered medical device to help radiologists detect lung nodules in chest X-rays

Retrieved on: 
Thursday, August 17, 2023
Heart, CT, University, Survival, Lung cancer, Oncology, Lung cancer screening, Lung, University of Colorado, ASCO, Radiology, X-ray, Patient, AUC, FDA, Health, Environment, Software, Medical device, Medical imaging

VisiRad XR is an AI-powered software that analyzes chest X-rays and highlights possible lung nodules and masses.

Key Points: 
  • VisiRad XR is an AI-powered software that analyzes chest X-rays and highlights possible lung nodules and masses.
  • VisiRad XR gives clinicians a closer look at often-overlooked lung lesions, potentially enabling identification of future lung cancers in outpatient and emergency department settings.
  • “Radiologists are looking for solutions to help elevate their performance and reduce burnout,” said Dr. Raj Chopra, Chief Medical Officer of IMIDEX.
  • Requiring no additional testing orders, VisiRad XR seeks to increase the number of detected lung nodules and masses in patients seen through routine care.

Median Technologies Reports Its Business Activity for the First Half of 2023 and Announces the First Step of Its Refinancing Plan

Retrieved on: 
Wednesday, July 12, 2023
Data Management, Biotechnology, Technology, Other Health, Health, Biometrics, Oncology, Health Technology, Medical Devices, Software, Artificial Intelligence, Medical device, CE, Euronext Growth, US, EU, Cave rescue, LCS, Bank statement, BofA Securities, Clinical trial, Lung cancer screening, Fruit, Burn, European Investment Bank, Convertible, MRMC, CSF, EIB, FDA, Pharmaceutical industry, LP

Median Technologies (Euronext Growth - ALMDT) reports today its business indicators for the first half of 2023 for the iCRO activity (non-audited figures) and the iBiopsy® activity.

Key Points: 
  • Median Technologies (Euronext Growth - ALMDT) reports today its business indicators for the first half of 2023 for the iCRO activity (non-audited figures) and the iBiopsy® activity.
  • "When it comes to our iBiopsy® LCS CADe/CADx Software as Medical Device, the design of our pivotal validation plan has been finalized since March 2023.
  • In Q2 2023, the Company's revenue stands at €5.8M, up by 3.6% from Q1 2023 and 13.7% compared to Q4 2022 revenue.
  • As at June 30, 2023, Median Technologies' cash and cash equivalents stand at €8.3M, compared to €13.1M at March 31, 2023, i.e.

RSNA: High Accuracy Artificial Intelligence Improves Lung Cancer Detection

Retrieved on: 
Tuesday, June 27, 2023
Linda, CT, Human, Society, Education, Doctor of Philosophy, OAK, Lung cancer, Research, Lung cancer screening, Radiological Society of North America, Tuberculosis, X-ray, Trust, Publishing, Radiation, Patient, Reading, Seoul National University, Clutch (eggs), Workload, Artificial intelligence, RSNA, Health, Medical imaging, Medical device, Radiology, New York University, AI

OAK BROOK, Ill., June 27, 2023 /PRNewswire-PRWeb/ -- Assistance from an artificial intelligence (AI) algorithm with high diagnostic accuracy improved radiologist performance in detecting lung cancers on chest X-rays and increased human acceptance of AI suggestions, according to a study published in Radiology, a journal of the Radiological Society of North America (RSNA).

Key Points: 
  • Researchers at Seoul National University looked at how these factors might influence the detection of malignant lung nodules during AI-assisted reading of chest X-rays.
  • Of the 120 chest radiographs assessed, 60 were from lung cancer patients (32 males) and 60 were controls (36 males).
  • In a second session, each group reinterpreted the X-rays, assisted by either a high- or low-accuracy AI.
  • Use of the high accuracy AI improved readers' detection performance to a greater extent than low-accuracy AI.